![]() |
INMB | Inmune Bio, Inc. |
Biological Products (no Diagnostic Substances) |
Book value per $ invested | $ 0.80 |
Leverage | 23.40% |
Market Cap | $ 35.9m |
PE | 0.00 |
Dividend Yield | 0.00% |
Profit | $ -55.4m |
Margin | -8643.37% |
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patients innate immune system to treat cancer, Alzheimers disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California.